BRCA1 and breast carcinoma: So, the presence of PARP1 inhibits the functioning of HR, causing mutations in BRAC proteins [108], and from various studies, it was found that ≈70% of mutated BRCA1 and ≈16–23% of mutated BRCA2 breast cancers are regarded as TNBCs [109].